NCT04952493 is a Phase 2 clinical trial of Anlotinib hydrochloride in Thyroid Cancer, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT04952493?

NCT04952493 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT04952493?

Interventions in NCT04952493: Anlotinib hydrochloride, Sodium Iodide I 131, Penpulimab.

What condition does NCT04952493 study?

NCT04952493 studies Thyroid Cancer.

Is NCT04952493 still recruiting?

NCT04952493 is currently status unknown. Last updated 28 January 2022.

Last reviewed 2022-01-28 · How we verify

NCT04952493

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anlotinib or Penpulimab in Combination With RAI for DTC

Status unknown Phase 2 Last updated 28 January 2022

What this trial tests

Phase 2 trial testing Anlotinib hydrochloride in Thyroid Cancer in 42 participants. Status unknown.

Timeline

15 September 2021

Primary endpoint
20 July 2023

20 July 2024

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	42
Start date	15 September 2021
Primary completion	20 July 2023
Estimated completion	20 July 2024
Sites	1 location across China

Drugs / interventions tested

Anlotinib hydrochloride
Sodium Iodide I 131 — full drug profile →
Penpulimab (PENPULIMAB) — full drug profile →

Conditions studied

Thyroid Cancer — all drugs for Thyroid Cancer →

Sponsor

Peking Union Medical College Hospital

Who can join

18 and older, any sex, with Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the efficacy and safety of anlotinib in combination with I-131 in locally advanced/metastatic differentiated thyroid cancer. Anlotinib may stop the growth of tumor cells and improve iodine uptake.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update.
Ratajczak M, Gaweł D, Godlewska M. · · 2021 · cited 37× · PMID 34769260 · DOI 10.3390/ijms222111829
The Role of the Kinase Inhibitors in Thyroid Cancers.
Cuomo F, Giani C, Cobellis G. · · 2022 · cited 18× · PMID 35631627 · DOI 10.3390/pharmaceutics14051040
Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Cortas C, Charalambous H. · · 2023 · cited 7× · PMID 38255638 · DOI 10.3390/life14010022
Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer.
Herranz UA. · · 2022 · cited 3× · PMID 36202606 · DOI 10.1002/cam4.5105
Leveraging molecular targeted drugs and immune checkpoint inhibitors treat advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation.
Su JY, Huang T, Zhang JL, Lu JH, et al · · 2024 · cited 1× · PMID 38455407 · DOI 10.62347/ejaa3388

Verify or expand the search:

Other trials of Anlotinib hydrochloride

Trials testing the same drug.

NCT06476093 — SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer · NA · recruiting
NCT05193188 — A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma · Phase 2 · unknown
NCT05539118 — Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma · Phase 1, PHASE2 · not yet recruiting
NCT05883085 — A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL · Phase 2 · unknown
NCT04967625 — A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC · Phase 2 · unknown

Other recruiting trials for Thyroid Cancer

Currently open trials in the same condition.

NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting
NCT07370675 — Active Surveillance for Bethesda IV Thyroid Nodules · NA · recruiting
NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
NCT07438847 — 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer · Phase 1 · recruiting
NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04952493 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 28 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04952493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing